SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging as traders respond to an earnings beat and strong revenue guidance, fueling speculation of a potential short squeeze as the stock undergoes a fundamental re-rating. The community is actively debating the stock's valuation disconnect compared to AI peers, with bullish sentiment focused on the company's massive backlog and the possibility that shorts may soon be forced to cover.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is seeing significant momentum as investors digest upcoming investor day details and a massive share buyback program while sector rotation into memory and AI infrastructure fuels the rally. The community is actively debating the sustainability of this price action, with bulls pointing to strong fundamentals and potential short squeezes while bears remain skeptical of valuations and competitive headwinds.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors focus on upcoming clinical data presentations and the company's progress toward a planned BLA filing in late 2026 for its lead prostate cancer candidate. The community is actively debating the potential for a multibillion-dollar buyout, while closely monitoring manufacturing updates and institutional accumulation as the firm prepares for its next growth milestones.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is surging as investors cheer the official closure of the Northern Data acquisition and the scaling of the Quake AI infrastructure division, which has significantly shifted the stock's narrative toward high-growth AI compute. Community sentiment is overwhelmingly bullish, with active discussion focused on the potential for a massive short squeeze driven by record short interest and the strategic value of the company's unmonetized data center capacity.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist is trending as investors react to a significant new patent infringement action filed against Micron, Super Micro Computer, HPE, and Lenovo, which follows a major strategic settlement with Samsung. The community is actively discussing a surge in momentum, citing a raised price target from Roth Capital and increased optimism regarding potential upcoming settlements and a future NASDAQ relisting.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco Systems stock is experiencing significant volatility following an earnings report that featured a revenue beat and strong AI infrastructure demand, yet faced selling pressure due to concerns over gross margin contraction and high investor expectations. Investors are actively debating whether this pullback represents an attractive institutional accumulation opportunity or a broader warning sign for AI-related networking hardware.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is currently facing downward pressure as investors react to news of a potential European Union investigation into its Ceconomy acquisition, alongside broader market frustration over Chinese equity underperformance. Despite the dip, some community members continue to highlight the company's strong cash position and growth potential as long-term buying opportunities.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Holdings is experiencing extreme volatility following a mixed earnings report where record-breaking revenue and raised guidance were overshadowed by a significant earnings per share miss. While the community is deeply divided between optimistic long-term investors highlighting strong backlog growth and cynical traders pointing to dilution and management's past performance, the stock remains a focal point for intense debate over its future valuation and institutional manipulation.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is experiencing high volatility as investors weigh the company's raised full-year guidance and significant RPO against a revenue miss and concerns regarding profitability. Community sentiment is deeply polarized, with some bulls emphasizing the company's fast inference technology and enterprise partnerships, while bears highlight the high valuation, heavy stock-based compensation, and upcoming share lockup expirations.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as investors monitor the impact of a newly scheduled March trial date in the high-stakes antitrust lawsuit challenging the Warner Bros. Discovery merger. The community is actively debating the significance of potential settlement concessions, such as divesting assets like CNN, while keeping a close watch on persistent institutional short-selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO...

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and...

BioLineRx (BLRX) Q1 2026 Earnings Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, May 27, 2026 - Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of...

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting PR Newswire TEL AVIV, Israel and OSLO...

BioLineRx to Report First Quarter 2026 Results on May 27, 2026

BioLineRx to Report First Quarter 2026 Results on May 27, 2026 BioLineRx to Report First Quarter 2026 Results on May 27, 2026 PR Newswire TEL AVIV, Israel, May 20, 2026 Management to Hold Conference Call at 8:30 a.m. EDTTEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX...

BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models

BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-resistant cancer models.read more...

BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts

BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with...

BLRX Stock Surges Pre-Market On Cancer Trial Catalyst – Eyes 50-DMA Breakout For First Time In Nearly 2 Months

Equity

The biotech firm announced the dosing of its first patient in an early-stage trial of its new cancer therapy.

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a...

$BLRX Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.00
• Reported revenue of $0.48M up 87.06% YoY
• BioLineRx is maintaining its cash runway guidance into the first half of 2027 with $17.4M on its balance sheet as of March 31, 2026.

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Bioline Rx Ltd - ADR

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.00	--	--	N/A
Q1 '26	-$1.04	$0.00	100.00%	BEAT
Q4 '25	-$0.38	--	--	N/A
Q3 '25	-$0.67	$0.00	100.00%	BEAT
Q2 '25	-$0.35	$0.00	100.00%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings